SE520730C2 - Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel - Google Patents

Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel

Info

Publication number: SE520730C2
Authority: SE; Sweden
Prior art keywords: blood; brain barrier; substance; drug; therapeutic drug
Prior art date: 1995-01-20

Application number

SE9500209A

Other languages

English (en)

Swedish (sv)

Other versions

SE9500209D0 (sv

SE9500209L (sv

Inventor

Eskil Elmer

Hiroyuki Uchino

Marcus Keep

Merab Kokaia

Zaal Kokaia

Haakan Widner

Qi Zhao

Keiko Uchino

Original Assignee

Eskil Elmer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-20

Filing date

1995-01-20

Publication date

2003-08-19

1995-01-20 Application filed by Eskil Elmer filed Critical Eskil Elmer

1995-01-20 Priority to SE9500209A priority Critical patent/SE520730C2/sv

1995-01-20 Publication of SE9500209D0 publication Critical patent/SE9500209D0/xx

1996-01-18 Priority to JP52220296A priority patent/JP3643380B2/ja

1996-01-18 Priority to NZ300699A priority patent/NZ300699A/en

1996-01-18 Priority to US08/860,898 priority patent/US5972924A/en

1996-01-18 Priority to EP96901587A priority patent/EP0813420B1/de

1996-01-18 Priority to AU45924/96A priority patent/AU712974B2/en

1996-01-18 Priority to CA002210241A priority patent/CA2210241C/en

1996-01-18 Priority to ES96901587T priority patent/ES2176432T3/es

1996-01-18 Priority to CZ19972336A priority patent/CZ291233B6/cs

1996-01-18 Priority to SI9630476T priority patent/SI0813420T1/xx

1996-01-18 Priority to RU97114608/14A priority patent/RU2194527C2/ru

1996-01-18 Priority to CN96192572A priority patent/CN1123359C/zh

1996-01-18 Priority to AT96901587T priority patent/ATE218360T1/de

1996-01-18 Priority to PCT/SE1996/000036 priority patent/WO1996022104A1/en

1996-01-18 Priority to DK96901587T priority patent/DK0813420T3/da

1996-01-18 Priority to DE69621603T priority patent/DE69621603T2/de

1996-01-18 Priority to APAP/P/1997/001049A priority patent/AP734A/en

1996-01-18 Priority to PT96901587T priority patent/PT813420E/pt

1996-07-21 Publication of SE9500209L publication Critical patent/SE9500209L/

1997-08-20 Priority to MX9706362A priority patent/MX9706362A/es

2003-08-19 Publication of SE520730C2 publication Critical patent/SE520730C2/sv

Links

238000011282 treatment Methods 0.000 title claims abstract description 24
239000003814 drug Substances 0.000 title claims abstract description 23
229940079593 drug Drugs 0.000 title abstract description 18
230000000324 neuroprotective effect Effects 0.000 title description 11
208000029028 brain injury Diseases 0.000 title description 5
230000006931 brain damage Effects 0.000 title description 4
231100000874 brain damage Toxicity 0.000 title description 4
201000006474 Brain Ischemia Diseases 0.000 title 1
230000008499 blood brain barrier function Effects 0.000 claims abstract description 54
210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 54
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 27
229930105110 Cyclosporin A Natural products 0.000 claims abstract description 24
108010036949 Cyclosporine Proteins 0.000 claims abstract description 24
229960001265 ciclosporin Drugs 0.000 claims abstract description 24
210000002569 neuron Anatomy 0.000 claims abstract description 16
229940126585 therapeutic drug Drugs 0.000 claims description 69
229930182912 cyclosporin Natural products 0.000 claims description 44
108010036941 Cyclosporins Proteins 0.000 claims description 38
239000000126 substance Substances 0.000 claims description 37
239000000203 mixture Substances 0.000 claims description 29
208000028389 Nerve injury Diseases 0.000 claims description 24
210000004556 brain Anatomy 0.000 claims description 24
230000008764 nerve damage Effects 0.000 claims description 24
239000002552 dosage form Substances 0.000 claims description 21
238000009472 formulation Methods 0.000 claims description 20
238000002347 injection Methods 0.000 claims description 20
239000007924 injection Substances 0.000 claims description 20
239000013543 active substance Substances 0.000 claims description 18
239000000243 solution Substances 0.000 claims description 18
239000000654 additive Substances 0.000 claims description 17
239000003085 diluting agent Substances 0.000 claims description 11
210000000278 spinal cord Anatomy 0.000 claims description 11
230000000302 ischemic effect Effects 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
206010021143 Hypoxia Diseases 0.000 claims description 7
239000002207 metabolite Substances 0.000 claims description 7
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
229930195725 Mannitol Natural products 0.000 claims description 6
239000000594 mannitol Substances 0.000 claims description 6
235000010355 mannitol Nutrition 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
239000012530 fluid Substances 0.000 claims description 5
230000007246 mechanism Effects 0.000 claims description 5
241000282412 Homo Species 0.000 claims description 3
230000005779 cell damage Effects 0.000 claims description 3
208000037887 cell injury Diseases 0.000 claims description 3
230000002503 metabolic effect Effects 0.000 claims description 3
230000035699 permeability Effects 0.000 claims description 3
102000007327 Protamines Human genes 0.000 claims description 2
108010007568 Protamines Proteins 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
229940088679 drug related substance Drugs 0.000 claims 8
239000008186 active pharmaceutical agent Substances 0.000 claims 6
230000002925 chemical effect Effects 0.000 claims 3
239000005022 packaging material Substances 0.000 claims 3
230000000472 traumatic effect Effects 0.000 claims 3
230000001146 hypoxic effect Effects 0.000 claims 2
230000001537 neural effect Effects 0.000 claims 1
229950008679 protamine sulfate Drugs 0.000 claims 1
238000000034 method Methods 0.000 abstract description 20
210000004027 cell Anatomy 0.000 abstract description 9
230000002490 cerebral effect Effects 0.000 abstract description 7
238000002483 medication Methods 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
208000018152 Cerebral disease Diseases 0.000 abstract 1
230000006378 damage Effects 0.000 description 15
210000000944 nerve tissue Anatomy 0.000 description 14
-1 cyclic poly-amino acid Chemical class 0.000 description 13
239000007788 liquid Substances 0.000 description 10
230000006870 function Effects 0.000 description 9
239000004090 neuroprotective agent Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
230000030833 cell death Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
208000014674 injury Diseases 0.000 description 8
239000002775 capsule Substances 0.000 description 7
210000000653 nervous system Anatomy 0.000 description 7
239000000843 powder Substances 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
210000003027 ear inner Anatomy 0.000 description 6
238000001802 infusion Methods 0.000 description 6
208000028867 ischemia Diseases 0.000 description 6
230000004112 neuroprotection Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
210000004291 uterus Anatomy 0.000 description 6
230000000694 effects Effects 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
230000007954 hypoxia Effects 0.000 description 5
210000005036 nerve Anatomy 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
230000008733 trauma Effects 0.000 description 5
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
238000009434 installation Methods 0.000 description 4
230000008774 maternal effect Effects 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
210000001428 peripheral nervous system Anatomy 0.000 description 4
230000008569 process Effects 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
210000003454 tympanic membrane Anatomy 0.000 description 4
230000002792 vascular Effects 0.000 description 4
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
208000001953 Hypotension Diseases 0.000 description 3
108090001030 Lipoproteins Proteins 0.000 description 3
102000004895 Lipoproteins Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010047163 Vasospasm Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
230000009056 active transport Effects 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000001627 cerebral artery Anatomy 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000007906 compression Methods 0.000 description 3
JAMYKWXSCJFSSX-OKJSGIQHSA-N cyclosporin A metabolite M26 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@@H]2OC(CCO)C[C@H]2C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C JAMYKWXSCJFSSX-OKJSGIQHSA-N 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
230000003073 embolic effect Effects 0.000 description 3
210000000609 ganglia Anatomy 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
210000004498 neuroglial cell Anatomy 0.000 description 3
210000003625 skull Anatomy 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
238000011287 therapeutic dose Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 2
ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 description 2
AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 2
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010028570 Myelopathy Diseases 0.000 description 2
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 2
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
241001149964 Tolypocladium Species 0.000 description 2
208000030886 Traumatic Brain injury Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
210000005058 airway cell Anatomy 0.000 description 2
238000010171 animal model Methods 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000000133 brain stem Anatomy 0.000 description 2
210000005252 bulbus oculi Anatomy 0.000 description 2
210000004004 carotid artery internal Anatomy 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000006071 cream Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
OPQZHVFVHOLQNE-JFGKHBSWSA-N cyclosporin A metabolite M18 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@@H]2OC(CCO)C[C@H]2C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C OPQZHVFVHOLQNE-JFGKHBSWSA-N 0.000 description 2
YIRMXRJTZYYXFH-DCMUSGNWSA-N cyclosporin A metabolite M25 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\CO)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CN(C)C1=O)C(C)C YIRMXRJTZYYXFH-DCMUSGNWSA-N 0.000 description 2
108010019248 cyclosporin C Proteins 0.000 description 2
108010019594 cyclosporin D Proteins 0.000 description 2
108010019249 cyclosporin G Proteins 0.000 description 2
230000034994 death Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
210000000883 ear external Anatomy 0.000 description 2
210000000959 ear middle Anatomy 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
239000006260 foam Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
239000000819 hypertonic solution Substances 0.000 description 2
229940021223 hypertonic solution Drugs 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000004407 iron oxides and hydroxides Substances 0.000 description 2
208000037906 ischaemic injury Diseases 0.000 description 2
230000007775 late Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000002690 local anesthesia Methods 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
238000009593 lumbar puncture Methods 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
210000001595 mastoid Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002324 mouth wash Substances 0.000 description 2
229940051866 mouthwash Drugs 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000003463 organelle Anatomy 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
230000009984 peri-natal effect Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
231100000572 poisoning Toxicity 0.000 description 2
230000000607 poisoning effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000009291 secondary effect Effects 0.000 description 2
208000020431 spinal cord injury Diseases 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
210000001644 umbilical artery Anatomy 0.000 description 2
210000003954 umbilical cord Anatomy 0.000 description 2
210000003606 umbilical vein Anatomy 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
HTHPJMCQQNKDHH-UHFFFAOYSA-N 33-(1,6-dihydroxy-2-methylhexyl)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone Chemical compound CCC1NC(=O)C(C(O)C(C)CCCCO)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O HTHPJMCQQNKDHH-UHFFFAOYSA-N 0.000 description 1
XDHBIXMGTCHICW-UHFFFAOYSA-N 5,6-dimethylcyclohex-2-ene-1-carboxylic acid Chemical class C1(C(C(CC=C1)C)C)C(=O)O XDHBIXMGTCHICW-UHFFFAOYSA-N 0.000 description 1
108010082694 8-hydroxy-6,7-dihydro-(4-(2-butenyl)-4,N-dimethylthreonine)cyclosporin Proteins 0.000 description 1
108010056567 AM 19 Proteins 0.000 description 1
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
208000018652 Closed Head injury Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
241000272184 Falconiformes Species 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010061213 Iatrogenic injury Diseases 0.000 description 1
208000032984 Intraoperative Complications Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000007792 addition Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000010001 cellular homeostasis Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000019771 cognition Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
BEDOPNJARNLRIQ-ZGBBRUJZSA-N cyclosporin A metabolite M1A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C(O)=O)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BEDOPNJARNLRIQ-ZGBBRUJZSA-N 0.000 description 1
WTDYXGYWROEPQE-FQYNWTTGSA-N cyclosporin A metabolite M9 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CN(C)C1=O)C(C)C WTDYXGYWROEPQE-FQYNWTTGSA-N 0.000 description 1
PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine a Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000012282 endovascular technique Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
150000002118 epoxides Chemical class 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
230000002727 hyperosmolar Effects 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
201000009941 intracranial hypertension Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006210 lotion Substances 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000036244 malformation Effects 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
ORDWWEGBCSTOOK-UHFFFAOYSA-N oxygen(2-) propane-1,2-diol titanium(4+) Chemical compound [O-2].[O-2].[Ti+4].CC(O)CO ORDWWEGBCSTOOK-UHFFFAOYSA-N 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000009518 penetrating injury Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
230000004224 protection Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
208000005809 status epilepticus Diseases 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
210000000331 sympathetic ganglia Anatomy 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical compound O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 description 1
229960005155 tirilazad Drugs 0.000 description 1
230000019432 tissue death Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SE9500209A 1995-01-20 1995-01-20 Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel SE520730C2 (sv)

Priority Applications (19)

Application Number	Priority Date	Filing Date	Title
SE9500209A SE520730C2 (sv)	1995-01-20	1995-01-20	Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
PT96901587T PT813420E (pt)	1995-01-20	1996-01-18	Tratamento da isquemia cerebral e danos cerebrais com agente neuroprotector
CZ19972336A CZ291233B6 (cs)	1995-01-20	1996-01-18	Léčivo proti nervovému inzultu
RU97114608/14A RU2194527C2 (ru)	1995-01-20	1996-01-18	Способ лечения церебральной ишемии и церебрального повреждения нейропротекторным средством
US08/860,898 US5972924A (en)	1995-01-20	1996-01-18	Treatment of cerebral ischemia and cerebral damage with neuroprotective agents
EP96901587A EP0813420B1 (de)	1995-01-20	1996-01-18	Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln
AU45924/96A AU712974B2 (en)	1995-01-20	1996-01-18	Treatment of cerebral ischemia and cerebral damage with neuroprotective agent
CA002210241A CA2210241C (en)	1995-01-20	1996-01-18	Pharmaceutical composition containing cyclosporin for treating a human with nervous insult
ES96901587T ES2176432T3 (es)	1995-01-20	1996-01-18	Tratamiento de isquemia cerebral y lesion cerebral mediante un agente neuroprotector.
JP52220296A JP3643380B2 (ja)	1995-01-20	1996-01-18	神経保護薬による脳虚血及び脳障害の治療
SI9630476T SI0813420T1 (en)	1995-01-20	1996-01-18	Treatment of cerebral ischemia and cerebral damage with neuroprotective agent
NZ300699A NZ300699A (en)	1995-01-20	1996-01-18	Treatment of cerebral ischemia and cerebral damage with neuroprotective agents, particularly cyclosporin a
CN96192572A CN1123359C (zh)	1995-01-20	1996-01-18	用神经保护剂治疗脑局部缺血和脑损伤
AT96901587T ATE218360T1 (de)	1995-01-20	1996-01-18	Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln
PCT/SE1996/000036 WO1996022104A1 (en)	1995-01-20	1996-01-18	Treatment of cerebral ischemia and cerebral damage with neuroprotective agent
DK96901587T DK0813420T3 (da)	1995-01-20	1996-01-18	Behandling af hjerneischæmi og hjerneskader med et neurobeskyttende middel
DE69621603T DE69621603T2 (de)	1995-01-20	1996-01-18	Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln
APAP/P/1997/001049A AP734A (en)	1995-01-20	1996-01-18	Method of treating a human with nervous insult with cyclosporin.
MX9706362A MX9706362A (es)	1995-01-20	1997-08-20	Tratamiento para isquemia cerebral y daño cerebral con agentes neuroprotectores.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9500209A SE520730C2 (sv)	1995-01-20	1995-01-20	Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel

Publications (3)

Publication Number	Publication Date
SE9500209D0 SE9500209D0 (sv)	1995-01-20
SE9500209L SE9500209L (sv)	1996-07-21
SE520730C2 true SE520730C2 (sv)	2003-08-19

Family

ID=20396911

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9500209A SE520730C2 (sv)	1995-01-20	1995-01-20	Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel

Country Status (18)

Country	Link
US (1)	US5972924A (de)
EP (1)	EP0813420B1 (de)
JP (1)	JP3643380B2 (de)
CN (1)	CN1123359C (de)
AP (1)	AP734A (de)
AT (1)	ATE218360T1 (de)
AU (1)	AU712974B2 (de)
CA (1)	CA2210241C (de)
CZ (1)	CZ291233B6 (de)
DE (1)	DE69621603T2 (de)
DK (1)	DK0813420T3 (de)
ES (1)	ES2176432T3 (de)
MX (1)	MX9706362A (de)
NZ (1)	NZ300699A (de)
PT (1)	PT813420E (de)
RU (1)	RU2194527C2 (de)
SE (1)	SE520730C2 (de)
WO (1)	WO1996022104A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19711795C2 (de) *	1997-03-21	2001-03-08	Apogepha Arzneimittel Gmbh	Verwendung von Cyclosporin für die Behandlung von Myokardinfarkten und deren Folgen
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
EP1138692A1 (de)	2000-03-29	2001-10-04	Erasmus Universiteit Rotterdam	Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US20040202645A1 (en) *	2003-04-08	2004-10-14	Khan Nisar Ahmed	Administration of gene-regulatory peptides
US6921751B1 (en) *	1998-05-20	2005-07-26	Erasmus Universiteit Rotterdam	Immunoregulator
US6844315B2 (en)	1998-05-20	2005-01-18	Erasmus Universiteit Rotterdam	Immunoregulator
US20050227925A1 (en) *	2004-04-08	2005-10-13	Robbert Benner	Compositions capable of reducing elevated blood urea concentration
US20030220258A1 (en)	2001-12-21	2003-11-27	Robbert Benner	Treatment of ischemic events
US8680059B2 (en) *	1998-05-20	2014-03-25	Biotempt B.V.	Oligopeptide acetate and formulations thereof
AP1040A (en) *	1998-09-17	2002-01-30	Panacea Biotec Ltd	A novel composition containing cyclosporin.
WO2000016794A1 (en) *	1998-09-23	2000-03-30	Marcus Keep	Neuroimmunophilins for selective neuronal radioprotection
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
CA2368937A1 (en) *	1999-04-13	2000-10-19	North Shore-Long Island Jewish Research Institute	Prevention of brain damage in stroke
JP2003508512A (ja)	1999-09-08	2003-03-04	ギルフォードファーマシュウティカルズインコーポレイテッド	非ペプチド性サイクロフィリン結合化合物とその用途
DE19961733A1 (de) *	1999-12-21	2001-06-28	Ciclomulsion Ag	Cyclosporin(e) enthaltende hypertone pharmazeutische Zubereitung zur Anwendung bei neurologischen Erkrankungen und als Neuroprotektivum sowie Verfahren zu ihrer Herstellung
KR20010069066A (ko) *	2000-01-12	2001-07-23	이종원	저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
US7358330B2 (en)	2001-03-29	2008-04-15	Biotempt B.V.	Immunoregulatory compositions
CA2404430A1 (en)	2000-04-07	2001-10-18	Albert S. Lee	Methods and apparatus for thermally affecting tissue
US6660026B2 (en)	2000-10-05	2003-12-09	Seacoast Technologies, Inc.	Multi-tipped cooling probe
US6656971B2 (en)	2001-01-25	2003-12-02	Guilford Pharmaceuticals Inc.	Trisubstituted carbocyclic cyclophilin binding compounds and their use
US6936589B2 (en) *	2001-09-28	2005-08-30	Albert T. Naito	Parenteral delivery systems
MXPA04003625A (es)	2001-10-19	2004-12-02	Sotechnika Inc	Sintesis de analogos de ciclosporina.
US7501391B2 (en) *	2001-12-21	2009-03-10	Biotempt B.V.	Treatment of transplant survival
US20080318871A1 (en) *	2001-12-21	2008-12-25	Khan Nisar A	Treatment of neurological disorders
US20030220261A1 (en) *	2001-12-21	2003-11-27	Khan Nisar Ahmed	Treatment of iatrogenic disease
US20080242837A1 (en) *	2001-12-21	2008-10-02	Khan Nisar A	Peptide compositions
US20040013661A1 (en) *	2001-12-21	2004-01-22	Gert Wensvoort	Stratification
US7786084B2 (en) *	2001-12-21	2010-08-31	Biotempt B.V.	Treatment of burns
US20030224995A1 (en) *	2001-12-21	2003-12-04	Khan Nisar Ahmed	Treatment of burns
US20030220257A1 (en) *	2001-12-21	2003-11-27	Robbert Benner	Treatment of trauma
US7560433B2 (en)	2001-12-21	2009-07-14	Biotempt B.V.	Treatment of multiple sclerosis (MS)
US20030220260A1 (en) *	2001-12-21	2003-11-27	Khan Nisar Ahmed	Peptide compositions
EP1633383A4 (de) *	2003-03-27	2008-05-21	Janssen Pharmaceutica Nv	Verwendung von erythropoietin bei der rekonvaleszenz nach einem schlaganfall
RU2265415C2 (ru) *	2003-05-19	2005-12-10	Челябинский государственный институт лазерной хирургии	Способ реваскуляризации инфарктных очагов головного мозга
RU2275195C2 (ru) *	2003-06-19	2006-04-27	Наталья Борисовна Кармен	Средство для защиты головного мозга от гипоксически-ишемического повреждения
RU2255739C2 (ru) *	2003-07-14	2005-07-10	Оренбургская государственная медицинская академия	Способ лечения ишемического инсульта в острейший период
US20090227505A1 (en) *	2004-01-07	2009-09-10	Biotempt B.V.	Methods and uses for protein breakdown products
DE602005019582D1 (de) *	2004-08-30	2010-04-08	Seo Hong Yoo	Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
US8420602B2 (en) *	2004-09-14	2013-04-16	Landon C. G. Miller	Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7074775B2 (en) *	2004-09-14	2006-07-11	Miller Landon C G	Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
JP4846799B2 (ja) *	2005-07-05	2011-12-28	バイオテンプトベー．フェー．	腫瘍の治療
EP1864692A1 (de)	2006-06-07	2007-12-12	Biotempt B.V.	Verwendung von peptiden zum Schutz von Strahlenschäden
BRPI0715633A2 (pt) *	2006-08-23	2013-07-02	Univ Montana	mÉtodo de reduÇço de dano em cÉlula neuronal
DK2120991T3 (da) *	2007-02-12	2014-04-28	Biotempt Bv	Behandling af traumatisk blødning med korte oligopeptider
EP3375449A1 (de) *	2010-03-15	2018-09-19	Stealth Peptides International, Inc.	Kombinationstherapien mit cyclosporin und aromatischen kationischen peptiden
RU2475233C2 (ru) *	2010-12-01	2013-02-20	Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН	Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
BR112013014890B1 (pt)	2010-12-15	2023-10-24	Contravir Pharmaceuticals, Inc	Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
CN102784102A (zh) *	2012-08-28	2012-11-21	赵继红	一种河豚毒素口服液态制剂及其制备方法
US10123969B2 (en)	2015-10-15	2018-11-13	Wisconsin Alumni Research Foundation	Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
EP3801217A4 (de) *	2018-05-30	2022-07-20	Zap Surgical Systems, Inc.	Radiochirurgische neuromodulation in der nähe von kritischen strukturen
WO2021048871A1 (en)	2019-09-15	2021-03-18	Celagenex Research (India) Pvt. Ltd.	Synergistic bioactive compositions for treating neurological disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1138164A1 (ru) *	1963-04-25	1985-02-07	Shadurskij Konstantin S	Антигистаминное средство "димебон
US4117118A (en) *	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
US5273754A (en) *	1992-03-27	1993-12-28	Mann Morris A	Appetite suppressant composition and method relating thereto

1995
- 1995-01-20 SE SE9500209A patent/SE520730C2/sv not_active IP Right Cessation
1996
- 1996-01-18 DK DK96901587T patent/DK0813420T3/da active
- 1996-01-18 ES ES96901587T patent/ES2176432T3/es not_active Expired - Lifetime
- 1996-01-18 CN CN96192572A patent/CN1123359C/zh not_active Expired - Lifetime
- 1996-01-18 DE DE69621603T patent/DE69621603T2/de not_active Expired - Lifetime
- 1996-01-18 US US08/860,898 patent/US5972924A/en not_active Expired - Lifetime
- 1996-01-18 RU RU97114608/14A patent/RU2194527C2/ru active
- 1996-01-18 EP EP96901587A patent/EP0813420B1/de not_active Expired - Lifetime
- 1996-01-18 NZ NZ300699A patent/NZ300699A/en not_active IP Right Cessation
- 1996-01-18 AU AU45924/96A patent/AU712974B2/en not_active Expired
- 1996-01-18 PT PT96901587T patent/PT813420E/pt unknown
- 1996-01-18 CA CA002210241A patent/CA2210241C/en not_active Expired - Lifetime
- 1996-01-18 AP APAP/P/1997/001049A patent/AP734A/en active
- 1996-01-18 AT AT96901587T patent/ATE218360T1/de active
- 1996-01-18 WO PCT/SE1996/000036 patent/WO1996022104A1/en not_active Ceased
- 1996-01-18 JP JP52220296A patent/JP3643380B2/ja not_active Expired - Lifetime
- 1996-01-18 CZ CZ19972336A patent/CZ291233B6/cs not_active IP Right Cessation
1997
- 1997-08-20 MX MX9706362A patent/MX9706362A/es unknown

Also Published As

Publication number	Publication date
CZ291233B6 (cs)	2003-01-15
JPH11504617A (ja)	1999-04-27
CN1123359C (zh)	2003-10-08
US5972924A (en)	1999-10-26
CN1178469A (zh)	1998-04-08
DE69621603T2 (de)	2002-09-19
RU2194527C2 (ru)	2002-12-20
PT813420E (pt)	2002-10-31
AU4592496A (en)	1996-08-07
AU712974B2 (en)	1999-11-18
EP0813420A1 (de)	1997-12-29
DK0813420T3 (da)	2002-09-30
JP3643380B2 (ja)	2005-04-27
CA2210241A1 (en)	1996-07-25
ES2176432T3 (es)	2002-12-01
DE69621603D1 (de)	2002-07-11
CA2210241C (en)	2000-06-20
EP0813420B1 (de)	2002-06-05
MX9706362A (es)	1998-07-31
SE9500209D0 (sv)	1995-01-20
WO1996022104A1 (en)	1996-07-25
AP9701049A0 (en)	1997-10-31
CZ233697A3 (cs)	1998-07-15
ATE218360T1 (de)	2002-06-15
SE9500209L (sv)	1996-07-21
NZ300699A (en)	1998-05-27
AP734A (en)	1999-02-15

Legal Events

Date	Code	Title	Description
2015-03-03	NUG	Patent has lapsed

Publication	Publication Date	Title
SE520730C2 (sv)	2003-08-19	Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
WO2022048197A1 (zh)	2022-03-10	α-细辛脑在制备预防或治疗缺血性脑卒中药物中的应用
WO2018113027A1 (zh)	2018-06-28	白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
RU2418601C2 (ru)	2011-05-20	Средство, обладающее гепатопротекторным, детоксицирующим и регенерирующим действием
WO2024235082A1 (zh)	2024-11-21	沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用
CN114288309A (zh)	2022-04-08	一种包含白头翁皂苷b5作为有效成分的促进生发的组合物
WO2009015561A1 (en)	2009-02-05	The use of leonurine and compositions thereof
EP4205734B1 (de)	2025-05-21	Alpha-asaron zur verwendung bei der behandlung von hämorrhagischem schlaganfall
US20040033946A1 (en)	2004-02-19	Cell damage inhibitor
Stancioiu et al.	2019	Post-stroke recovery of motor function with a new combination of medicines-A pilot study
AU766095B2 (en)	2003-10-09	Neuroimmunophilins for selective neuronal radioprotection
EP1091750B1 (de)	2009-09-02	Cerebrospinal und vaskulär wirksame pharmazeutische zubereitung und verfahren zu ihrer herstellung
AU2023222825A1 (en)	2023-09-28	Medication
CN105963287A (zh)	2016-09-28	复方组合物及其医药用途
WO2023138280A1 (zh)	2023-07-27	促进生发组合物、促进生发药物及应用
CN121714621A (zh)	2026-03-24	香青兰总黄酮在制备预防或治疗自身免疫性脱髓鞘疾病药物中的应用
CN113712981A (zh)	2021-11-30	甜菜碱组合物及其应用
MXPA01003029A (en)	2003-11-07	Neuroimmunophilins for selective neuronal radioprotection
JP2023513534A (ja)	2023-03-31	鎌状赤血球症に関連する血管閉塞性クリーゼを処置するための方法
CN109528699A (zh)	2019-03-29	芬乐胺在制备神经保护药物中的应用